New robotic surgery vs. ultrasound: which focal therapy wins for prostate cancer?

NCT ID NCT05610852

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two treatments for low-to-intermediate risk prostate cancer: a new robotic surgery that removes part of the prostate through a single small incision, and high-intensity focused ultrasound (HIFU) that uses sound waves to destroy cancer cells. About 276 men will be randomly assigned to one of the two procedures. The main goal is to see which treatment better prevents cancer from coming back, based on MRI scans and biopsies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Single-port robotic partial prostatectomy and high-intensity focused ultrasound (HIFU)

What this could lead to

If successful, this could show which focal therapy is more effective at controlling prostate cancer with fewer side effects, potentially becoming a standard treatment option.

What could go wrong

This is a single-center study, and results may not apply to all patients. Both procedures carry risks like infection, bleeding, or urinary problems, and the trial is still recruiting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Glickman Urological & Kidney Institute, Cleveland Clinic Foundation, Case Comprehensive Cancer Center

    RECRUITING

    Cleveland, Ohio, 44195, United States

    Contact Email: •••••@•••••